Skip to main content
. 2020 Jun 15;36(8):e3335. doi: 10.1002/dmrr.3335

FIGURE 3.

FIGURE 3

Effects of treatments on exploratory cardiopulmonary exercise testing (CPX) variables. Canagliflozin resulted in significant improvements in lean peak oxygen consumption (VO2), A, ventilatory anaerobic threshold (VAT), B, and RER‐matched VO2, C, compared to sitagliptin in a time_x_group interaction. Data are presented as mean ± SD. LM, lean mass measured with dual‐energy X‐ray absorptiometry; MD, mean difference between groups